Category: Vaccine

Page 130«..1020..129130131132..140150..»

Experimental cancer vaccine shows benefits against melanoma – WPBF West Palm Beach

December 14, 2023

An investigational mRNA vaccine used along with immunotherapy continues to show benefit for people with high-risk forms of the skin cancer melanoma, the drugmakers said Thursday.Related video above: New vaccine shows potential for lung cancer treatmentAt a three-year follow-up with trial participants who had had a stage III or IV melanoma fully removed but were at high risk of the cancer coming back, those who got the vaccine from Moderna along with Merck's Keytruda immunotherapy had a 49% lower risk of recurrence or death and a 62% lower risk of distant tumor cell spread or death compared with those who got Keytruda alone, the companies said in a news release.A two-year follow-up had found a 44% lower risk of recurrence or death and a 65% lower risk of distant metastasis or death in people who got Keytruda and the vaccine, called mRNA-4157/V940, compared with those who got Keytruda alone.About a quarter of the trial participants who got Keytruda plus the vaccine reported serious adverse events related to the treatment, compared with about 20% for those who got only Keytruda. The most common side effects attributed to the vaccine were fatigue, pain at the injection site and chills.The U.S. Food and Drug Administration first approved Keytruda, which boosts the immune system's ability to detect and fight cancer cells, for the treatment of certain cancers in 2014. The agency has granted a breakthrough therapy designation to mRNA-4157/V940 combined with Keytruda. This status expedites the development and review of drugs that are intended to treat a serious condition and that preliminary clinical evidence indicates may be a substantial improvement over available therapies.The data from the Phase 2b trial of the therapies has not been peer-reviewed or published in a professional journal. Moderna and Merck say they have begun Phase 3 trials on stage IIB-IV melanoma and non-small-cell lung cancer, and they plan to expand the research to include further types of tumors.According to the American Cancer Society, melanoma accounts for about 1% of all skin cancers, but it causes a majority of skin cancer deaths. The group estimated that in 2023, about 100,000 new melanomas would be diagnosed in the U.S., and almost 8,000 people would die from melanoma.CNN's Jamie Gumbrecht contributed to this report.

An investigational mRNA vaccine used along with immunotherapy continues to show benefit for people with high-risk forms of the skin cancer melanoma, the drugmakers said Thursday.

Related video above: New vaccine shows potential for lung cancer treatment

At a three-year follow-up with trial participants who had had a stage III or IV melanoma fully removed but were at high risk of the cancer coming back, those who got the vaccine from Moderna along with Merck's Keytruda immunotherapy had a 49% lower risk of recurrence or death and a 62% lower risk of distant tumor cell spread or death compared with those who got Keytruda alone, the companies said in a news release.

A two-year follow-up had found a 44% lower risk of recurrence or death and a 65% lower risk of distant metastasis or death in people who got Keytruda and the vaccine, called mRNA-4157/V940, compared with those who got Keytruda alone.

About a quarter of the trial participants who got Keytruda plus the vaccine reported serious adverse events related to the treatment, compared with about 20% for those who got only Keytruda. The most common side effects attributed to the vaccine were fatigue, pain at the injection site and chills.

The U.S. Food and Drug Administration first approved Keytruda, which boosts the immune system's ability to detect and fight cancer cells, for the treatment of certain cancers in 2014. The agency has granted a breakthrough therapy designation to mRNA-4157/V940 combined with Keytruda. This status expedites the development and review of drugs that are intended to treat a serious condition and that preliminary clinical evidence indicates may be a substantial improvement over available therapies.

The data from the Phase 2b trial of the therapies has not been peer-reviewed or published in a professional journal. Moderna and Merck say they have begun Phase 3 trials on stage IIB-IV melanoma and non-small-cell lung cancer, and they plan to expand the research to include further types of tumors.

According to the American Cancer Society, melanoma accounts for about 1% of all skin cancers, but it causes a majority of skin cancer deaths. The group estimated that in 2023, about 100,000 new melanomas would be diagnosed in the U.S., and almost 8,000 people would die from melanoma.

CNN's Jamie Gumbrecht contributed to this report.

Read more:

Experimental cancer vaccine shows benefits against melanoma - WPBF West Palm Beach

Nurses need ‘support and time’ to deliver new vaccination strategy plans – Nursing in Practice

December 14, 2023

Primary care nurses must be given appropriate support, resources and time in order to deliver the ambitions of the newly published vaccination strategy in England, Nursing in Practice has been told.

Leading nurses have welcomed NHS Englands new strategy which suggests vaccinations will become part of a one-stop shop, with nurses and colleagues set to expand the offer of blood pressure tests and other health checks and advice alongside routine vaccinations.

The long-awaited national vaccination strategy document, published on Wednesday, also said that local health teams will have more flexibility to locate vaccine services in convenient local places such as community centres, sport facilities and places of worship.

In addition, from 2025/26 people will be able to access their own vaccination record through the NHS App and book vaccinations.

Independent nurse consultant and immunisation specialist Helen Donovan was pleased to see the strategy launch and its ambitions around easing up the way that people can make appointments to be vaccinated.

However, she stressed that the time it takes for nurses to carry out vaccination appointments needed more consideration.

For example, she questioned whether practice nurses would have the capacity to do a blood pressure check alongside vaccinations, particularly where several vaccines are needed.

While nurses strive to ensure they make every contact count, Ms Donovan said this depended on having the time, resource and the capacity to do so.

What nurses and other clinicians say to me is we all want to make every contact count, but we dont always have the time to do it, said Ms Donovan, who is also a Queens Nurse.

In addition, she noted that nurses were increasingly telling me that they are lucky if they get 10-minute slots for childrens vaccines, despite guidance from the Royal College of Nursing (RCN) stating that 20-minute slots are required for most childrens appointments where the schedule is complex.

My worry is that to do those sorts of consultations safely, you need more time, she said.

Ms Donovan stressed it was also important to consider the education and training needs of nurses giving vaccinations, including annual updates, and the time and funding this also required to facilitate.

Overarchingly, Ms Donovan also highlighted how we need funding to facilitate the strategy and more registered nurses in primary care settings generally.

This was echoed by RCN professional lead for primary care Heather Randle who also warned of the support and resources nurses needed to deliver this work.

She told Nursing in Practice that the strategy was a significant and important development for public health.

However, there is a chronic shortage of nursing staff to provide these, and they need support and resources to deliver this programme of essential vaccines, added Ms Randle.

Primary care nurses are already at the forefront of vaccination programs, and they will tell you that giving vaccines are never just about the injections.

They fully appreciate how vaccination appointments provide the opportunity to carry out a health and wellbeing check.

In addition, Ms Randle warned it was important to ensure that increased opportunities to be vaccinated do not dilute that opportunity to check on the patient and their family.

Read this article:

Nurses need 'support and time' to deliver new vaccination strategy plans - Nursing in Practice

Booking a jab to become as easy as booking a cab with NHS App – Latest Pharmacy News | Business | Magazine – Pharmacy Business

December 14, 2023

NHS staff will offer blood pressure tests and other health checks and advice, alongside routine vaccinations

The NHS England has developed and published a new vaccination strategy with an aim to increase national uptake of lifesaving vaccinations, and protect people against a range of diseases.

Getting vaccinations will become easier than ever before, as the NHS App is being expanded with more additional features.

Improved booking features such as new in-App bookings, invitation alerts and appointment notifications will make booking a jab as easy as booking a cab, NHS leaders said.

The NHS App overhaul will also include improved access to medical records, meaning users will be able to see their routine vaccination status over the coming months and years, making it easier for them to identify any missed vaccinations in their history.

More than 33 million people are already signed up to the NHS App, and currently users can only view their COVID and flu vaccination status.

Alongside routine vaccinations, NHS staff will offer blood pressure tests and other health checks and advice, which means vaccinations will become part of a one-stop shop.

The NHS vaccination strategy also includes expansion of community outreach, including setting up of vaccine services in convenient local places such as community centres, sport facilities and places of worship.

Health Minister Maria Caulfield commented: To ensure as many people get vaccinated as possible, we need to make sure the programme fits around peoples lives.

The Vaccine Strategy will build on the brilliant work already underway to make it easier than ever to get vaccinated and to reach people who would not typically come forward for their jabs. Whether its booking via the app or stopping in while at parents evening with your children we are unveiling new, innovative ways of getting these lifesaving jabs and easing pressure on the NHS.

Get on the NHS App and see just how easy it is to get your jab, she added.

NHS Chief Executive Amanda Pritchard informed that users of their app will be able to access their full vaccine status in a matter of seconds and book jabs with a simple swipe and tap.

And well continue to expand the amazing work of NHS staff, volunteers and partners to introduce even more pop-up sites in the heart of our local communities. So, when you are invited for any of your vaccinations, please do book without delay it could be lifesaving, she said.

Steve Russell, National Director for Vaccinations and Screening for NHS England, highlighted that vaccination is one of the best ways to boost public health, second only to clean water.

He said: We want to see even more people supported to take up the offer of lifesaving vaccinations its the best way to protect you and those around you from illnesses which can be fatal, so please do come forward if invited, and if youre unsure or have questions, the NHS is here to help.

NHS England noted that this strategy is for people and organisations involved in the commissioning, planning and delivery of NHS vaccination services in England.

More:

Booking a jab to become as easy as booking a cab with NHS App - Latest Pharmacy News | Business | Magazine - Pharmacy Business

NHS to expand NHS App to allow patients to view records and book jabs – Digital Health

December 14, 2023

The NHS said Wednesday that it will expand the NHS app to allow more people to view their vaccination record and book in for vaccines.

NHS England said its newvaccination strategy will outline how getting vaccinations will be made easier than ever before, including through expansion of the NHS App, one-stop shops and community outreach. It said millions more people will be able to view their full vaccination record and book jabs over the months and years to come.

It also said expansion of the app will include improved access to medical records and provide patients with a personal history of potentially life-saving vaccines, such as HPV and MMR.

Improved booking features will include new in-App bookings, invitation alerts and appointment notifications, which NHS leaders said in the statement will make booking a jab as easy as booking a cab.

As part of the changes, parents of children and young people will increasingly be able to see the vaccination status of their children on the App and there will be new information and advice on how to book appointments.

Last week marked the anniversary of the worlds first ever Covid-19 vaccination given to 93-year-old Maggie Keenan in Coventry on the 8 December 2020 and todays NHS vaccination strategy builds on the world-leading NHS Covid-19 vaccine programme, which allowed adults to book their own vaccine appointments online, and to get vaccinated in a range of non-NHS settings.

Health and care professionals will focus efforts on going into the heart of communities to protect unvaccinated people who are less well-served by traditional health services taking vaccines close to peoples homes and offering in-person support to improve vaccine confidence, as well as offering the chance to get a jab.

Creating a one-stop shop

Vaccinations will become part of a one-stop shop with NHS staff set to expand the offer of blood pressure tests and other health checks and advice, alongside routine vaccinations, while local health teams will have more flexibility to locate vaccine services in convenient local places such as community centres, sport facilities and places of worship.

Around nine in 10 children have had their pre-school immunisations and flu vaccination rates are among the highest in the world, but this new blueprint for vaccination will support even higher uptake rates and bring the NHS closer to eliminating serious diseases like cervical cancer.

Amanda Pritchard, chief executive of the NHS in England noted that the NHS Covid-19 vaccination programme has delivered more than 156 million Covid jabs and saved tens of thousands of lives, and that the new vaccination strategy aimed to build on this success.

Through the NHS app, well make sure booking a jab can be as easy as booking a cab so millions more people can get vaccinated users will be able to access their full vaccine status in a matter of seconds and book jabs with a simple swipe and tap.

And well continue to expand the amazing work of NHS staff, volunteers and partners to introduce even more pop-up sites in the heart of our local communities. So, when you are invited for any of your vaccinations, please do book without delay it could be lifesaving, she added.

Over 33 million people are already signed up to the NHS App. Currently, most NHS App users can view their Covid and flu vaccination status via the NHS App, but the NHS will be increasing the visibility of routine vaccine-preventable diseases, making it easier for people to identify any missed vaccinations in their history.

Booking and receiving more than one vaccine in a single visit will also become easier, building on a big year-on-year increase in the number of winter flu and Covid-19 vaccines offered at the same time.

This has been supported by a joint online and telephone booking service and by combined invitations, both for the first time, as part of the current winter vaccines campaign.

Professor Dame Jenny Harries, chief executive of the UK Health Security Agency (UKHSA), said: The link between uptake rates and vaccine confidence and accessibility is critical and I welcome this renewed focus by NHS England on innovative delivery approaches responding to local need.

Infectious diseases hit hardest on the most vulnerable and vaccination is a critical tool in reversing health inequalities.

Rachel Power, chief executive of the Patients Association, added: Being able to check which vaccines you or your children have had via the NHS App will be popular with many people, as will the opportunity to book in for a vaccine appointment and get a reminder. These expansions of the App will help patients manage their health.

View original post here:

NHS to expand NHS App to allow patients to view records and book jabs - Digital Health

KFF COVID-19 Vaccine Monitor: MAGA Republicans Relationship With COVID-19 Vaccines – KFF

December 14, 2023

The KFF COVID-19 Vaccine Monitor has been tracking intentions to get a COVID-19 vaccine since December 2020, when the initial vaccine first became available. Throughout the past three years, partisanship has continued to play an outsized role in predicting both intentions to get a COVID-19 vaccine as well as other pandemic-related attitudes and behaviors. With the latest COVID-19 vaccine rollout, Republicans are once again among the groups least likely to report having gotten the updated shot. This data note examines how vaccine attitudes and uptake differ between Republicans who sit on different sides of a particular ideological divide within Republican Party support of the Make America Great Again (MAGA) movement.

The MAGA movement has attracted many Republicans and Republican-leaning independents, with six in ten (58%) saying they support the MAGA movement, representing about one quarter (23%) of all U.S. adults, according to the latest KFF Tracking Poll.

Generally, MAGA supporting Republicans tend to be older and have lower levels of education than Republicans who do not support the MAGA movement, with a larger share of MAGA Republicans being ages 50 and older (58% vs. 41%) and having less than a college degree (81% vs. 53%). MAGA supporting Republicans and Republicans who do not support the MAGA movement look similar across gender, race, and ethnicity.

Majorities of adults across partisan groups have reported receiving at least one dose of the COVID-19 vaccine that has been on the market since December 2020, though larger shares of Republicans compared to Democrats and independents remained resistant, with at least a quarter saying they would definitely not get a COVID-19 vaccine throughout the three years of KFF COVID-19 Vaccine Monitor surveys.

The November COVID-19 Vaccine Monitor finds that among Republicans and Republican-leaning independents, similar majorities of both those who support the MAGA movement (60%) and those who do not support the MAGA movement (70%) say they have received at least one dose of a COVID-19 vaccine (10 percentage points is within the margin of sampling error).

However, Republicans under 50 years old who support the MAGA movement are particularly resistant to getting a COVID-19 vaccine, with about four in ten saying they have received at least one dose, 20 percentage points lower than their non-MAGA supporting counterparts (39% vs. 59%). Given the increased vulnerability of adults ages 50 and older to the virus, and consistent with our findings that across party lines, older people have been more likely to get the COVID-19 vaccine, large majorities of older MAGA and non-MAGA supporting Republicans ages 50 and older report having gotten a COVID-19 dose.

The newest COVID-19 vaccine recently became available in September of this year, with somewhat muted uptake compared to initial vaccine uptake. As of early November, two in ten adults say they have gotten the updated vaccine including one in three Democrats (32%), 16% of independents, and 12% of Republicans. Among Republicans, alignment with the MAGA movement is a strong predictor of vaccine intentions with supporters of the MAGA movement the fiercest in their opposition to the latest shot.

Among Republicans and Republican-leaning independents, about one in four (26%) of those who do not support MAGA say they have gotten or probably or definitely will get the latest updated COVID-19 vaccine, compared to about one in six (17%) of those who support MAGA saying they have gotten or plan to get the vaccine.

Most Republicans, regardless of MAGA support, say they will not get the latest updated COVID-19 vaccine with nearly two-thirds (63%) of MAGA Republicans saying they will definitely not get the newest vaccine, a slightly larger share than the half of their non-MAGA counterparts (52%) who say the same. The difference between Republican MAGA supporters and non-supporters in the share who have gotten the updated COVID-19 vaccine or say they will persists even after controlling for other demographics of age, gender, community type (such as urban, rural, or suburban communities), education, and household income.

In addition to being among the least likely to be vaccinated against COVID-19 at all, younger MAGA Republicans are among the most adamant that they will definitely not get the updated vaccine. Seven in ten (70%) MAGA supporting Republicans under age 50 say they will definitely not get the updated shot, compared to 54% of Republicans and leaners in this age group who do not support the MAGA movement (and 34% of the public overall).

As of September, almost six in ten (57%) non-MAGA identifying Republicans said they had already gotten or definitely will get the flu shot this season, compared to 43% of MAGA supporting Republicans. Interestingly, Republicans who do not identify with the MAGA movement are not significantly more likely than MAGA Republicans to say they normally get an annual flu shot. This could suggest that the MAGA impact on vaccine uptake could be a relatively new phenomenon that public health officials may be facing in the years to come.

The differences between Republican MAGA supporters and non-supporters are not only evident in their uptake of vaccines, but also in their assessment of the safety of different types of vaccines. Republicans and Republican-leaning independents who support the MAGA movement are less likely than their non-MAGA counterparts to express confidence in the safety of COVID-19 vaccines (29% vs. 44%), respiratory syncytial virus, or RSV, vaccines (41% vs. 61%), and flu vaccines (53% vs. 74%).

Follow this link:

KFF COVID-19 Vaccine Monitor: MAGA Republicans Relationship With COVID-19 Vaccines - KFF

NHS England launches central vaccination strategy | UK Healthcare News – National Health Executive

December 14, 2023

The plan includes an expansion to the NHS app which will allow patients to book appointments through the app, see invitation alerts and get appointment notifications.

People will also have better access to medical records through the app, with parents able to check the vaccination status of their children online.

NHS England says it aims to fully implement theses proposals, and the entire strategy, by 2025/26.

The NHS also intends to strike deeper into the community and build on existing initiatives like school vaccination teams attending parents evenings, family clinics at childrens hospitals and wellbeing hubs.

Community work will centre around protecting underserved areas and improving vaccine confidence.

NHS Englands chief executive, Amanda Pritchard, said: Through the NHS app, well make sure booking a jab can be as easy as booking a cab so millions more people can get vaccinated users will be able to access their full vaccine status in a matter of seconds and book jabs with a simple swipe and tap.

Vaccines will become part of the one-stop-shop service, with NHS staff set to expand the offering of blood pressure tests and other healthcare advice.

Professor Dame Jenny Harries, the chief executive of the UK Health Security Agency, added: The link between uptake rates and vaccine confidence and accessibility is critical and I welcome this renewed focus by NHS England on innovative delivery approaches responding to local need.

Health minister, Maria Caulfield, commented: To ensure as many people get vaccinated as possible, we need to make sure the programme fits around peoples lives.

She continued: The Vaccine Strategy will build on the brilliant work already underway to make it easier than ever to get vaccinated and to reach people who would not typically come forward for their jabs.

Image credit: iStock

Read more:

NHS England launches central vaccination strategy | UK Healthcare News - National Health Executive

Getting your jabs will soon be ‘as easy as booking a cab’, say NHS chiefs – Express

December 14, 2023

91-year-old Margaret Keenan gets her Covid-19 booster vaccine

Getting jabs against a range of diseases will soon be as easy as booking a cab, the NHS has promised. Easier access to vaccine records via the NHS app and one-stop-shops where people can get their shots alongside other health checks are among measures set out in a new vaccination strategy on Wednesday.

Community outreach measures could also see vaccination teams attend school parents evenings to discuss the importance of immunisation.

Health bosses said the plans would boost uptake of vital jabs and bring the country closer to elimination of preventable diseases such as cervical cancer.

Amanda Pritchard, NHS England chief executive, said: Just over three years ago Maggie Keenan was the first person in the world to receive an approved Covid-19 jab.

Our vision for the future of vaccinations published today sets out how we plan to build on this huge success and save even more lives.

READ MORE: The Covid symptoms you should be looking out for in the lead up to Christmas

Through the NHS app, well make sure booking a jab can be as easy as booking a cab so millions more people can get vaccinated users will be able to access their full vaccine status in a matter of seconds and book jabs with a simple swipe and tap.

More than 156 million Covid jabs have been delivered since December 8 2020, saving tens of thousands of lives.

Meanwhile, the human papillomavirus vaccine has been found to cut rates of cervical cancer among women who receive it when aged 12 to 13.

However, uptake of some vaccinations - including childhood jabs to combat meningitis, polio, diphtheria and tetanus - have fallen recently.

Coverage decreased for 12 out of 14 childhood vaccine measures reported in 2022-23, with none meeting the 95 percent target.

Steve Russell, NHS Englands national director for vaccinations and screening, said jabs were one of the best ways to boost public health, second only to clean water.

He said plans included taking vaccines into the heart of communities where we see lower uptake rates, so offering vaccines at pop-up clinics and health hubs in shopping centres, and local schools teams going into parents evenings to address barriers to people consenting to their childs vaccinations.

Health minister Maria Caulfield said: To ensure as many people get vaccinated as possible, we need to make sure the programme fits around peoples lives.

Whether its booking via the app or stopping in while at parents evening with your children we are unveiling new, innovative ways of getting these lifesaving jabs and easing pressure on the NHS."

Read the original:

Getting your jabs will soon be 'as easy as booking a cab', say NHS chiefs - Express

Mpox (Monkeypox) Vaccine Triggers Equally Strong Immune Response in Smaller-Than-Usual Doses & in People with … – NYU Langone Health

December 14, 2023

Delivering the two-dose mpox vaccine, called JYNNEOS, in smaller than the usual doses approved by the U.S. Food and Drug Administration (FDA), and by injection between layers of the skin rather than by the standard route under the skin, produced a detectable immune response, a new study shows. This response occurred in recipients whether they were living with or without HIV.

Led by researchers at NYU Grossman School of Medicine, the study showed no significant difference in the strength of the immune response (as gauged by the amount of detectable IgG antibodies, immune proteins that help kill the mpox virus) between most of those who received their vaccine injections in small doses between layers of the skin (intradermally) and those who received it as prescribed in full-dose injections just beneath the skin (subcutaneously). Because of limited space between skin layers, intradermal injections can only accommodate small doses, while larger doses generally require subcutaneous injections.

The smaller doses, about one-fifth of the usual full dose and spread out by as long as three months, were designed to stretch the short supply of vaccine available after an outbreak of the disease, previously known as monkeypox, in May 2022. The IgG antibodies were detected in some cases more than six months after the second and final dose of the vaccine.

The smaller-dose regimen of the JYNNEOS vaccine, which was originally designed to protect against smallpox but also known to be effective against its relative mpox, was approved by the U.S. government during the shortage in August 2022. Mpox infection in a small number of cases can be life-threatening.

More than 3,800 New York City residents were infected with the virus, spread by bodily fluids and skin contact, including during sex, and mostly over the course of the outbreak in the summer of 2022. The mpox vaccine is now routinely recommended by the Centers for Disease Control and Prevention (CDC) for people at risk. About 155,000 New Yorkers were vaccinated during this time, mostly using smaller doses.

Researchers say that a resurgence in the Democratic Republic of the Congo in November 2023, with nearly 13,000 suspected cases and some 600 deaths, poses the risk of another outbreak beyond Africa, to other regions and to New York City in particular.

Reported in the New England Journal of Medicine online December 14, researchers say they found that people fully vaccinated with two smaller doses had an immune response four times stronger than those who did not complete the vaccination series and had only one dose.

Our study shows that smaller vaccine doses of mpox vaccine administered in two doses, spread out over weeks to months, were similar to the full (subcutaneous) FDA-approved dose, said study co-lead investigator and infectious disease specialist Angelica Cifuentes Kottkamp, MD. Implementing the smaller dose was a good emergency measure in the face of immediate shortages of the vaccine, said Dr. Kottkamp, who is an assistant professor in the Department of Medicine at NYU Langone Health.

Among its other findings, the study showed that those previously vaccinated against smallpox as part of routine childhood vaccination programs also had a stronger immune response than those who had had no previous smallpox vaccination. Levels of detectable IgG antibodies in blood samples were 2.7-times higher among those previously vaccinated against smallpox who additionally received the JYNNEOS vaccine compared to those who were not dually vaccinated.

Because of their weakened immune systems, people living with HIV are particularly vulnerable to co-infection. The study found no difference in the magnitude of the immune response between vaccinated people living with HIV (with immune CD4 cell counts above 200) and vaccinated people who are HIV negative.

Our findings offer valuable support to the people most at risk of being infected with mpox that in the case of an mpox resurgence, infectious disease specialists have sufficient vaccination tools and knowledge to deal with it effectively in the short term, said study senior investigator Mark J. Mulligan, MD.

Dr. Mulligan, the Thomas S. Murphy Professor in the Department of Medicine at NYU Langone, where he also serves as the director of the Vaccine Center and the Division of Infectious Diseases and Immunology, says more research is needed to determine if additional vaccine doses against mpox are needed for optimal protection and to know how long, in months or years, protection lasts. The amount of emergency stockpiles of mpox vaccine and the ability to ramp up vaccine production quickly in case of future outbreaks, he notes, also need to be examined.

Some 145 New Yorkers vaccinated against mpox participated in the new study. Most were men (81 percent), and almost all (89 percent) self-identified as being LGBTQ+. Thirty-five (24 percent) were people living with HIV, and 29 (20 percent) had previously been vaccinated against smallpox.

The global public health emergency declared by the World Health Organization as a result of the mpox viral outbreak ended in May 2023, one year after it started. However, infections continue to occur globally, with more than 91,000 confirmed cases as of October 31 this year, including 167 deaths in 116 countries. In the United States, more than 31,000 people have been infected, according to the CDC, with 55 deaths. More than 1.2 million doses of the mpox vaccine have been administered in the United States.

Funding support for the study was provided through National Institutes of Health grants R01AI148574 and 75N93021C00014, the New York City Department of Health and Mental Hygiene, and the Blavatnik Family Foundation.

Besides Dr. Kottkamp and Dr. Mulligan, other NYU Langone researchers involved in this study are co-lead investigators Marie I. Samanovic-Golden, PhD, and Ralf Duerr, MD, PhD; and study co-investigators Aaron Oom, PhD, and Hayley Belli, PhD. Other study investigators are Jane Zucker, MD, MSc, and Jennifer Rosen, MD, at the NYC Department of Health and Mental Hygiene.

David March Phone: 212-404-3528 David.March@NYULangone.org

Link:

Mpox (Monkeypox) Vaccine Triggers Equally Strong Immune Response in Smaller-Than-Usual Doses & in People with ... - NYU Langone Health

Breast cancer vaccine now in early clinical trials: What to know – ABC15 Arizona in Phoenix

December 13, 2023

A new vaccine being studied in early clinical trials may hold the potential to help some women with breast cancer, a disease that affects one in every eight women in the United States, according to the Centers for Disease Control and Prevention.

The vaccine, which has not yet been named, targets triple-negative breast cancer, the most aggressive and deadliest form of breast cancer.

The vaccine's first clinical trial, the results of which were published last week, found that the vaccine caused no significant side effects and achieved a good immune response in 75% of patients in the trial.

The Phase 1 trial was composed of 16 women who received three vaccinations administered once every two weeks, according to Anixa Biosciences, Inc., the California-based company that is developing the vaccine.

The trial was conducted at the Cleveland Clinic and was supported by a grant from the U.S. Department of Defense, according to Anixa.

"This vaccine is designed to direct the immune system to destroy TNBC cancer cells through a mechanism that has never previously been utilized for cancer vaccine development," Dr. Amit Kumar, chairman and CEO of Anixa Biosciences, said in a statement announcing the trial's results. "We look forward to reviewing additional data as the trial continues to completion, and we are in the planning stages of the Phase 2/3 studies of this vaccine."

The vaccine is currently being designed to stop the recurrence of cancer in patients who have already been treated for triple-negative breast cancer, according to Kumar. He said the next phase of research will focus on utilizing the vaccine to prevent the onset of triple-negative breast cancer.

ABC News chief medical correspondent Dr. Jennifer Ashton, who was not involved in the research, said that while the vaccine is a promising development in the field of breast cancer research, it will be years before it is available to the general public.

"This could, and I want to emphasize could, start to be available in about five years or so," Ashton said of the breast cancer vaccine.

Ashton noted that vaccines already exist for several different types of cancers, including cervical, liver, and metastatic prostate cancer.

Those vaccines, and the new potential new vaccine for breast cancer, all focus on immunotherapy, Ashton explained. When a person develops cancer, the immune system doesn't attack the tumor on its own because the tumor is formed from the person's own cells, according to Ashton.

"Using the concept of immunotherapy now, there are clinical trials in progress that take a snippet from a person's actual tumor and then kind of fold it into, in a lot of cases, MRNA vaccine technology," Ashton said. "So, it lets that loose so that the person's immune system can actually fight its own cancer."

The breast cancer vaccine currently being researched targets a lactation protein, known as -lactalbumin, that is present in the majority of triple-negative breast cancer patients, according to Anixa.

When breast cancer develops, the vaccine instructs the immune system to fight off the tumor and keep it from growing.

Follow this link:

Breast cancer vaccine now in early clinical trials: What to know - ABC15 Arizona in Phoenix

Bronny James and what to know about heart health, COVID-19 and vaccines – ESPN

December 13, 2023

Baxter Holmes, ESPN Senior WriterDec 11, 2023, 08:00 AM ET

On July 24, 18-year-old USC freshman guard Bronny James -- the son of Los Angeles Lakers star LeBron James -- suffered cardiac arrest during a workout at USC. In January, Buffalo Bills safety Damar Hamlin, then 24, suffered cardiac arrest during a game against the Cincinnati Bengals. In June 2022, then-incoming USC freshman center Vince Iwuchukwu, then 19, suffered cardiac arrest during a workout. In June 2021, Danish midfielder Christian Eriksen, then 29, suffered cardiac arrest on the pitch during a Euro 2020 match.

In all four instances, the athletes received immediate care from trained specialists and survived. Hamlin, Iwuchukwu and Eriksen have all been cleared to return to play -- and, on Sunday, James made his season debut for USC in a 84-79 overtime loss against Long Beach State, scoring 4 points in 17 minutes of action off the bench.

James' return came after his family announced in August that he had a congenital heart defect that was treatable. Three months later, on Nov. 19, he went through pregame warmups for the first time and, 11 days later, doctors cleared him to return to play. On Thursday, James participated in his first full-contact practice for USC.

James' situation -- along with those of Hamlin, Iwuchukwu and Eriksen -- drew international headlines and raised questions in and around the sports and medical communities about heart issues among young, seemingly healthy athletes. Studies have been commissioned by leading specialists, and cardiologists around the country have tried to address concerned parents, especially in the era of conspiracy theories and misinformation.

Today, after a yearslong pandemic and several rounds of new vaccines and boosters, cardiologists regularly face questions about how COVID-19 and its vaccines impact heart health.

"We are not seeing a signal that pre-COVID and post-COVID [cardiac] events are any different," said Dr. Matthew Martinez, director of the sports cardiology and hypertrophic cardiomyopathy center at Morristown Medical Center in New Jersey, and a consulting cardiologist for the National Basketball Players Association.

"What we are seeing, however, is that more people are being evaluated as a result of COVID. So we're making the diagnosis of underlying congenital heart disease in those who were unaware [they had it], like hypertrophic cardiomyopathy, more frequently than we did before. And because of the fear of myocarditis from COVID, more and more parents and more and more athletes are saying, 'Hey, I have these symptoms, and I'm worried about it,' and they're seeking medical attention."

2 Related

Myocarditis is the inflammation of the heart muscle, and it can be found in or develop from viral infections or sometimes in autoimmune diseases. "These inflammatory mediators get stuck inside the heart muscle, and they can make the heart muscles sluggish," said Dr. David J. Engel, director of the sports cardiology program at NewYork-Presbyterian/Columbia University Irving Medical Center. "And so the pumping strength of the heart goes down, and people can get really sick from it."

Hypertrophic cardiomyopathy is increased muscle thickness in the heart, and, according to Martinez, it's a common genetic heart disease found in about one in every 500 people worldwide, according to a 2015 study published in the Journal of the American College of Cardiology. "Most of whom live a normal lifespan and die from something else," said Dr. Steve Ommen, a cardiologist and medical director of the Mayo Clinic's hypertrophic cardiomyopathy clinic in Rochester, Minnesota.

It is, however, one of the known causes of cardiac arrest, according to Martinez.

Sudden cardiac arrest is when the heart is beating one minute, and then not beating the next, Martinez said, and the only way to get it pumping again is to use an automated external defibrillator (AED), which sends an electrical shock to the heart. (Cardiac arrest is different from a heart attack, which is when the heart arteries become blocked and the blood flow to the heart muscle is reduced, which leads to damage of the heart muscle. If that damage is extensive, it can cause cardiac arrest.)

"It's not someone who's in the hospital with symptoms of chest pain for the last three days or heart failure over the last few weeks, and they're getting worse and worse and worse, and then they die," Ommen said. "This is 24 hours from the first symptom to their death. And it generally is caused by electrical irregularities in the heart, which make the heart not effective in the way it pumps."

In many instances, though, the cause of the cardiac arrest is unknown.

In an effort to better understand the state of cardiac health among athletes, ESPN interviewed four leading cardiologists, several of whom work with professional and collegiate athletes, and examined recent peer-reviewed studies the cardiologists cited as foundational to these issues.

"Than the general population? No," said Dr. Thomas McGarry, an interventional and clinical cardiologist with Oklahoma Heart Hospital Physicians. "But there are certain athletes that are at risk."

McGarry cites a 2023 study of 76 NCAA and professional athletes who had genetic heart diseases and were allowed to return to play. "And of those 76 individuals, three people had problems, but they all survived because the institutions and/or teams knew what was going on and were able to take care of them very quickly with external defibrillators," he said.

Friday, Dec. 15 Lakers at Spurs, 7:30 p.m. Knicks at Suns, 10 p.m.

Friday, Dec. 22 Wizards at Warriors, 10 p.m.

All times Eastern

Ommen likewise notes that, generally, athletes are not at risk for more cardiac-related issues. "For recreational athletes, the answer is undoubtedly no," he said. "For those of us who aren't professional athletes, more exercise is always better. There are rare conditions like exercise-induced atrial fibrillation, which is abnormal heart rhythm, which is provoked by exercise. So there's a few individuals that we've identified over the last couple of years that have had that on professional sports teams, and generally gotten treated for it and returned to action. But that's kind of a rare thing."

Martinez said the same. "Exercise is medicine. Exercise is our best blood pressure management, it's our best cholesterol management, it's our best mental health management, it is a stress reliever," he said. "For people who are younger than the age of 40, heart-related cardiac risk is often a congenital problem. But for people over the age of 40, it is acquired heart artery disease [heart attacks]. In this group, the best way to prevent sudden cardiac death in that group is with exercise. So exercise doesn't promote risk; it diminishes risk."

It depends.

With myocarditis, "you're going to hold someone out and let that heart muscle heal," Martinez said. "And then once that muscle is healed, you're going to do a risk stratification evaluation by an expert -- an assessment to determine, in part, one's risk of a cardiac event -- to see that they are truly back to that minimal risk that they were in before the myocarditis. And we're going to do the same thing with hypertrophic cardiomyopathy."

Givony's big board: Top 25 prospects Complete Top 100 rankings for 2024 Latest mock draft: Collier at No. 1 NBA draft notebook: Surprise freshmen

Other cardiologists echoed this point. Engel cites guidelines from the American Heart Association and American College of Cardiology that a player with active myocarditis should refrain from exercise for three to six months and then be reassessed before returning to play.

"Nearly all of the time, once the inflammation settles down, the heart muscle is left in good condition," Engel said. "And if the markers of active inflammation are no longer present, then the athlete can return to play."

Martinez cites the aforementioned 2023 study, of which he is an author, that examined the 76 athletes who had genetic heart diseases. It shows that "having an underlying cardiac disease is not an automatic disqualification, that an athlete with myocarditis or hypertrophic cardiomyopathy continuing to play after careful review can be done," he said.

According to each cardiologist, the most common link, particularly in earlier COVID-19 variants, is myocarditis. That COVID-19 could lead to myocarditis wasn't unexpected, they say, as myocarditis can often be caused by viral infections.

"Viruses have caused myocarditis for as long as we know anything about viruses, and the COVID virus is not any different," Martinez said. "COVID is one of the viruses that can cause myocarditis. There was myocarditis before COVID, there will be myocarditis after COVID."

A 2021 study published in JAMA Cardiology -- which Martinez helped write -- examined 789 professional athletes with COVID-19 infection who underwent a post-COVID cardiac testing as recommended by the American College of Cardiology. Of that group, the prevalence of myocarditis was low: about 0.6%.

In a nationwide April 2021 study in the American Heart Association journal Circulation that examined 3,018 college athletes who had tested positive for COVID-19 and had a cardiac evaluation, heart issues were found in 21 -- or 0.7% -- of those athletes.

"It's not a strong link," Engel said.

All four cardiologists say heart issues are more likely to arise from COVID-19 viral infection than from the vaccines. Citing a 2023 peer-reviewed study in the international scientific journal Biomedicines, Martinez and Engel note that the rate of someone receiving a COVID-19 vaccine and then having myocarditis is 30 out of 100,000, or 0.03%.

"The concern of myocarditis should not be a justification for not taking the vaccine, because the incidence of myocarditis after the COVID vaccine is exceptionally low," Engel said.

See the original post:

Bronny James and what to know about heart health, COVID-19 and vaccines - ESPN

Page 130«..1020..129130131132..140150..»